H.C. Wainwright analyst Raghuram Selvaraju downgraded Aptinyx to Neutral from Buy without a price target after the NYX-458 Phase 2 trial failure led to a suspension of clinical activities. The company’s current situation may necessitate a transformative transaction in order to position the public entity on a path towards potentially generating value for shareholders, the analyst tells investors in a research note. The firm says it does not have any clarity on the type of transaction that Aptinyx could pursue.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on APTX:
- SVB Securities downgrades Aptinyx to Market Perform, lowers price target to 50c
- Aptinyx downgraded to Market Perform from Outperform at SVB Securities
- APTX Nosedives after Parkinson’s and Dementia Phase 2 Study Disappoints
- Aptinyx to resume trading at 4:35pm E.T.
- Aptinyx says Phase 2 Study of NYX-458 did not demonstrate sufficient efficacy